Bioventus, Inc. (BVS)
NASDAQ:BVS
Want to see BVS full AI Analyst Report?
BVS Stock Chart & Stats
$10.52
-$0.12(-1.26%)
At close: 4:00 PM EST
$10.52
-$0.12(-1.26%)
Day’s Range― - ―
52-Week Range$5.81 - $11.25
Previous CloseN/A
Volume116.12K
Average Volume (3M)662.69K
Market Cap
$710.88M
Enterprise Value$559.44M
Total Cash (Recent Filing)$35.85M
Total Debt (Recent Filing)$272.08M
Price to Earnings (P/E)20.3
Beta0.78
Next Earnings
Aug 11, 2026EPS Estimate
0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.42
Shares Outstanding67,748,050
10 Day Avg. Volume732,383
30 Day Avg. Volume662,688
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)2.69
Price to Sales (P/S)0.87
P/FCF Ratio6.94
Enterprise Value/Market Cap0.79
Enterprise Value/Revenue0.97
Enterprise Value/Gross Profit1.43
Enterprise Value/Ebitda5.42
Forecast
1Y Price Target
$14.33Price Target Upside36.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.78
Revenue Forecast (FY)$605.30M
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationSustained TTM operating and free cash flow, tightly linked to reported earnings, materially improves funding flexibility. Strong cash conversion supports ongoing reinvestment in growth (PNS/PRP/Ultrasonics), faster deleveraging, and reduces refinancing risk, making capital allocation decisions more durable across cycles.
Sharply Reduced Leverage And Healthier EquityMarked de-risking of the balance sheet—debt reduction and restored equity returns—lowers interest expense vulnerability and enhances strategic optionality. With management targeting <2.0x net leverage and visible deleveraging progress, the company gains durable capacity to invest, return capital, or withstand downturns.
Margin Recovery And Disciplined ReinvestmentHigh and improving gross margins plus raised EPS and cash guidance indicate structural profitability gains. Management is reinvesting incremental cash into prioritized, scalable areas (PNS, PRP, Ultrasonics, International), balancing margin targets with growth investments to sustain long-term operating leverage and earnings quality.
Bears Say
Uneven Revenue MomentumInconsistent revenue trends signal dependence on procedure volumes, distributor timing, and reimbursement dynamics. Durable earnings recovery hinges on steady top-line growth; if volumes or channel execution falter, prior profitability gains and cash flow strength could reverse, making sustained revenue acceleration a key structural risk.
Early-stage Growth Drivers Require RampCore growth initiatives (PNS, PRP, Ultrasonics) are commercially nascent and need time, clinical validation and training to scale. Execution risk is structural: prolonged ramp cycles or slower clinician adoption could delay revenue contributions and pressure ROI on the incremental investments management is deploying.
Outstanding Leverage Remains MaterialAlthough leverage has improved, a material absolute debt load and the need to hit net-leverage targets constrain capital allocation. Interest and principal obligations can limit long-term flexibility for M&A or expanded commercialization spending, and still-present leverage heightens sensitivity to adverse operating swings.
Bioventus News
BVS FAQ
What was Bioventus, Inc.’s price range in the past 12 months?
Bioventus, Inc. lowest stock price was $5.81 and its highest was $11.25 in the past 12 months.
What is Bioventus, Inc.’s market cap?
Bioventus, Inc.’s market cap is $710.88M.
When is Bioventus, Inc.’s upcoming earnings report date?
Bioventus, Inc.’s upcoming earnings report date is Aug 11, 2026 which is in 55 days.
How were Bioventus, Inc.’s earnings last quarter?
Bioventus, Inc. released its earnings results on May 06, 2026. The company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.069 by $0.081.
Is Bioventus, Inc. overvalued?
According to Wall Street analysts Bioventus, Inc.’s price is currently Undervalued.
Does Bioventus, Inc. pay dividends?
Bioventus, Inc. does not currently pay dividends.
What is Bioventus, Inc.’s EPS estimate?
Bioventus, Inc.’s EPS estimate is 0.22.
How many shares outstanding does Bioventus, Inc. have?
Bioventus, Inc. has 67,748,050 shares outstanding.
What happened to Bioventus, Inc.’s price movement after its last earnings report?
Bioventus, Inc. reported an EPS of $0.15 in its last earnings report, beating expectations of $0.069. Following the earnings report the stock price went up 2.247%.
Which hedge fund is a major shareholder of Bioventus, Inc.?
Currently, no hedge funds are holding shares in BVS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bioventus Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.33 (36.25% Upside)
$14.33 (36.25% Upside)
Blogger Sentiment
Bullish
BVS Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 359.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $105.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 5.4%
Last 30 Days ▲ 6.5%
Last 30 Days ▲ 6.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
29.90%
12-Months-Change
Fundamentals
Return on Equity
16.27%
Trailing 12-Months
Asset Growth
-5.91%
Trailing 12-Months
Company Description
Bioventus, Inc.
Bioventus Inc. is a global medical technology enterprise specializing in the development and market introduction of clinical solutions that activate and bolster the body's inherent regenerative processes. The company's diverse product range is categorized into three primary segments: Firstly, pain management offerings include minimally invasive joint pain injection therapies and advanced peripheral nerve stimulation devices. Secondly, their surgical innovations feature bone graft substitutes engineered to facilitate bone fusion and growth, thereby improving results in spinal and other orthopedic procedures. This segment also comprises ultrasonic instruments employed for precise bone sculpting, tumor excision, and tissue cleansing. Thirdly, restorative therapies encompass an advanced ultrasonic system for fracture repair, along with skin allografts, specialized products for chronic wound management, and sophisticated rehabilitation devices designed to aid in the recovery of leg and hand function. Bioventus's clientele consists of medical professionals across the entire orthopedic spectrum, such as specialists in sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery. These offerings are utilized in various clinical environments, including private clinics, ambulatory surgical centers, and hospital settings. Established in 2011, Bioventus Inc. maintains its corporate headquarters in Durham, North Carolina.
BVS Company Deck
BVS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong financial momentum: solid revenue growth (+7%), robust adjusted EBITDA expansion (+24%), improved margins and materially stronger cash flow (+$28M YoY), along with raised EPS and cash guidance. Management is accelerating targeted investments (primarily into PNS, PRP, Ultrasonics and International) and added senior leadership to scale new businesses. Offsetting items include a one-time favorable rebate that boosted Q1 results, near-term margin volatility as investments ramp, early-stage nature of new growth drivers, distributor inventory/timing headwinds in Pain, and a still-material debt balance ($272M) that remains a focus. Overall, the positives (growth, profitability, cash generation and proactive reinvestment) outweigh the manageable near-term challenges.View all BVS earnings summariesBVS Stock 12 Month Forecast
Average Price Target
$14.33
▲(36.25% Upside)
Technical Analysis
Ownership Overview
32.13% Insiders
8.61% Mutual Funds
48.92% Other Institutional Investors
0.08% Public Companies and
Individual Investors